Anti-inflammatory activity of hemantane on peripheral inflammation and lipopolysaccharide induced neuro-inflammation models

Hemantane is a novel antiparkinsonian drug that is undergoing clinical trials. Hemantane in the dosage range 10-40 mg/kg demonstrated anti-inflammatory activity and decreased statistically significantly the intensity of the exudative reaction in an acetic-acid peritonitis model in mice. Hemantane (10 mg/kg) in a neuro-inflammation model induced by lipopolysaccharide injection in rats prevented loss of body mass, development of forepaw akinesia contralateral to the operation, and smell disturbance. Keywords: Parkinson's disease, hemantane, neuro-inflammation, lipopolysaccharide, peripheral inflammation.